Association of H.pylori infection with gastric carcinoma:a Meta analysis

AIM: To follow the principles of evidence based medicine to reach the integrated results of these studies.METHODS: Twenty-one papers of case-control studies were selected, including 11 on gastric cancer, 7 on precancerous lesion of stomach and 3 on lymphoma of stomach: Meta analysis was used to sum up the odds ratios (OR) of these studies.RESULTS: H. Pylori vsgastric cancer (intestinal and diffuse type): the odds ratio from the fixed effect model is 3.0016(95% Cl 2.4197-3.7234, P < 0.001 ). H. Pylori vs precancerous lesion of stomach: a random effect model was used to calculate the summary odds ratio and its value is 2.5635 (95% Cl: 1.8477-3.5566, P < 0.01). H. Pylori vs lymphoma of stomach: though the quantity of literature is too small to make Meta analysis, the data of these 3 studies show that lymphoma of stomach is highly associated with H. Pylori infections.CONCLUSION: Since it had been revealed that H. Pylori infection pre-exists in gastric carcinoma and precancerous lesions, the results of Meta analysis present a strong evidence to support the conclusion that H. Pylori infection is a risk factor for gastric carcinoma.

Association between central serous chorioretinopathy and Helicobacter pylori infection: a systematic review and Meta-analysis

AIM:To investigate the association between central serous chorioretinopathy(CSC)and Helicobacter pylori(Hp)by summarizing all available evidence.METHODS:The Scopus,Embase,EBSCO,PubMed,Web of Science,and Cochrane Library databases for all relevant studies published from inception to October 2022 were searched,and manually searched for relevant reference lists as a supplement.Studies investigating the association between CSC and Hp infection were included.Finally,8 case-control studies were included in the Meta-analysis after study selection.RESULTS:The results showed no significant correlation between Hp infection and CSC[odds ratio(OR)1.89,95%confidential interval(CI)0.58–6.15,I2=96%,P=0.29].After subgroup analysis based on the degree of development of the study(developing/developed countries),it was found that the results of the two subgroups were the same as the whole,and no significant difference between the two subgroups existed.Meta-regression showed that the effect of sample size on heterogeneity among studies was more prominent(P<0.01,adjusted R^(2)=89.72%),which can explain 89.72%of the sources of heterogeneity.CONCLUSION:This Meta-analysis reveals no significant correlation between Hp infection and CSC,which still warrants further well-designed extensive sample studies to reach a more reliable conclusion and promote a better understanding of the treatment of CSC.

Estimate the Prevalence of Helicobacter pylori Infection among Diabetes & Non-Diabetes Mellitus Patients and Its Correlation with Malignant Gastritis Patients Attending in Lower Shabelle Region (Somalia)

Background: Several conducted studies have reported a higher and more frequent Helicobacter pylori infection rate in type 2 diabetes mellitus (T2DM). The aim of this study was to estimation the prevalence of H. pylori and its association between H. pylori infection and T2DM. Materials and Methods: A sectional-cross study was conducted based on 200 patients studded with socioeconomic characteristics through a questionnaire & H. pylori was diagnosed by serum anti-H. pylori immunoglobulin G (IgG) and IgA. Furthermore, patients were investigated for fasting blood glucose (FBG) levels, glycosylated hemoglobin (HbA1c), serum cholesterol, and other biochemistry parameters. Results: The findings showed The prevalence of Hp positive infection was significantly higher in the total sample was 134 with (67%). While 66 out of 200 patients with (33%) was H. pylori negative infection. of H. pylori. Further, the mean values were statistically significant for diabetes with H. pylori infection for IgG > 300 titer and IgA > 250 titer, regarding, HbA1C (7.52 ± 0.41) (P Conclusions: The current study revealed that H. pylori prevalence infections were significantly higher in diabetic patients studied compared to non-diabetic patients. Furthermore, T2DM patients infected with H. pylori positive reported a higher prevalence rate of symptoms than H. pylori negative.

Third-line and rescue therapy for refractory Helicobacter pylori infection: A systematic review

BACKGROUND Due to increasing resistance rates of Helicobacter pylori(H.pylori)to different antibiotics,failures in eradication therapies are becoming more frequent.Even though eradication criteria and treatment algorithms for first-line and second-line therapy against H.pylori infection are well-established,there is no clear recommendation for third-line and rescue therapy in refractory H.pylori infection.AIM To perform a systematic review evaluating the efficacy and safety of rescue therapies against refractory H.pylori infection.METHODS A systematic search of available rescue treatments for refractory H.pylori infection was conducted on the National Library of Medicine’s PubMed search platform based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.Randomized or non-randomized clinical trials and observational studies evaluating the effectiveness of H.pylori infection rescue therapies were included.RESULTS Twenty-eight studies were included in the analysis of mean eradication rates as rescue therapy,and 21 of these were selected for analysis of mean eradication rate as third-line treatment.For rifabutin-,sitafloxacin-,levofloxacin-,or metronidazole-based triple-therapy as third-line treatment,mean eradication rates of 81.6%and 84.4%,79.4%and 81.5%,55.7%and 60.6%,and 62.0%and 63.0%were found in intention-to-treat(ITT)and per-protocol(PP)analysis,respectively.For third-line quadruple therapy,mean eradication rates of 69.2%and 72.1%were found for bismuth quadruple therapy(BQT),88.9%and 90.9%for bismuth quadruple therapy,three-in-one,Pylera®(BQT-Pylera),and 61.3%and 64.2%for non-BQT)in ITT and PP analysis,respectively.For rifabutin-,sitafloxacin-,levofloxacin-,or metronidazole-based triple therapy as rescue therapy,mean eradication rates of 75.4%and 78.8%,79.4 and 81.5%,55.7%and 60.6%,and 62.0%and 63.0%were found in ITT and PP analysis,respectively.For quadruple therapy as rescue treatment,mean eradication rates of 76.7%and 79.2%for BQT,84.9%and 87.8%for BQT-Pylera,and 61.3%and 64.2%for non-BQT were found in ITT and PP analysis,respectively.For susceptibility-guided therapy,mean eradication rates as third-line and rescue treatment were 75.0%in ITT and 79.2%in PP analysis.CONCLUSION We recommend sitafloxacin-based triple therapy containing vonoprazan in regions with low macrolide resistance profile.In regions with known resistance to macrolides or unavailability of bismuth,rifabutin-based triple therapy is recommended.

Furazolidone-induced pulmonary toxicity in Helicobacter pylori infection:Two case reports

BACKGROUND Helicobacter pylori(H.pylori)infection is a global problem,causing significant morbidity and mortality.Furazolidone is recommended to eradicate H.pylori infections in China owing to the highly associated antibiotic resistance.CASE SUMMARY This article presents two cases of lung injury caused by furazolidone treatment of H.pylori infection and the relevant literature review.Two patients developed symptoms,including fever,cough,and fatigue after receiving a course of furazolidone for H.pylori infection.Chest computed tomography showed bilateral interstitial infiltrates.Laboratory studies revealed elevated blood eosinophil count.After discontinuing furazolidone with or without the use of corticosteroids,the symptoms improved rapidly.A PubMed database literature search revealed three reported cases of lung injury suggestive of furazolidone-induced pulmonary toxicity.CONCLUSION Clinicians should be aware of the side effects associated with the administration of furazolidone to eradicate H.pylori infection.

Helicobacter Pylori Infection and Gastroduodenal Lesions in Patients with Chronic Kidney Disease: A Comparative Study

Introduction: Gastroduodenal lesions are common in chronic kidney disease (CKD). They are linked to various factors including Helicobacter pylori infection (H. pylori). Few data are available in Africa on H. pylori infection and chronic kidney disease. The aim of this study was to assess the impact of H. pylori infection and to describe the gastroduodenal lesions found in patients with chronic kidney disease. Patients and Methods: A cross-sectional study was conducted, February 1st to May 31st, 2021, at the Douala General Hospital in Cameroon. We included patients with CKD classified as stages 3 to 5 according KDIGO classification, on hemodialysis or not, who agreed to participate in the study. They were matched with a “control” population including patients with normal renal function according to sex and age (ratio 1:2). Patients on antibiotics and/or proton pump inhibitors were excluded. We collected data from CKD patients and from medical records for non-CKD group. Each patient underwent an upper digestive endoscopy and identification of H. pylori using a urease rapid test. Logistic regression was used to identify independent associations for a significance level set at p Results: We included 99 patients including 33 with CKD and 66 control patients. Among patients with CKD, the predominance was male (n = 18/33 or 54.5%). The mean age was 51.2 ± 12.8 years. Arterial hypertension was the first etiology of CKD (n = 13 or 39.4%). The prevalence of H. pylori in patients with CKD was 63.6% versus 37.9% in control patients (p-value = 0.015). The main endoscopic lesions were erosive gastropathy (n = 14 or 42.4%) and erythematous gastropathy (n = 7 or 21.2%). Patients with CKD were 5 times more likely to have H. pylori infection (OR = 5.69;CI 95% 0.14 - 0.82;p = 0.017). Factors associated with H. pylori infection were chronic kidney disease (aOR = 1.02;CI 95% 0.14 - 0.82;p = 0.017) and hemodialysis (aOR = 10;CI 95% 1.08 - 91.9;p = 0.042). Conclusion: The prevalence of H. pylori infection is higher in patients with CKD. Endoscopic lesions are inflammatory. Factors associated with H. pylori infection are chronic kidney disease and hemodialysis.

The exposure of antibiotics on the eradication of bismuth quadruple therapy in H.pylori infection

Objective To analyze the impact of previous exposure to macrolide,quinolones and nitroimidazole antibiotics on eradication rate of bismuth quadruple therapy(BQT)in newly diagnosed patients with Helicobacter pylori(H.pylori).Methods A total of 469 patients with H.pylori initially treated at the Third Hospital of Peking University from September 2017 to August 2020 were retrospectively recruited.

Study on Professor Diangui Li's Medication Experience in Treating Atrophic Gastritis Concomitant with Helicobacter Pylori Infection Based on Data Mining

Objective Our objective was to explore the national traditional Chinese medicine by studying master Diangui Li's medication experience in treating atrophic gastritis(AG)concomitant with Helicobacter pylori(Hp)infection based on data mining,and to provide the reference for the clinical treatment of relevant diseases.Methods The Chinese medicine prescriptions of the patients'first visits to the Famous Doctors'Consultation Room in Hebei Provincial Hospital of Chinese Medicine from May 2019 to December 2022 were collected and frequency analysis of the Chinese herbs,association rules analysis of the Chinese herbs,and cluster analysis were conducted using the Famous Doctor Inheritance Assistance Platform.ResultsA total of 188 prescriptions were collected,with 136 kinds of Chinese herbs.The highest use frequency of Chinese herbs was 185 and the lowest was 1.There were 28 kinds of Chinese herbs with high use frequency.The top 10 herbs with the high use frequency include Baihuasheshecao(Hedyotis Diffusae Herba),Huanglian(Coptidis Rhizoma),Yinchen(Artemisiae Scopariae Herba),jigucao(Abriherba),Baishao(Paeoniae Radix Alba),Danggui(Angelicae Sinensis Radix),Banzhilian(Scutellariae Barbatae Herba),Baihe(Lili Bulbus),Zhishi(Auranti Immaturus Fructus),Chuanxiong(Chuanxiong Rhizoma).Chinese herbs with high frequency use are mostly heat-clearing herbs and qi-regulating herbs;the flavors of the herbs are mainly pungent,bitter,and sweet;the properties are mainly warm,cold,and neutral;the meridian tropism is mainly the spleen,liver,and stomach meridians.The core herbal medicines are Huanglian(Coptidis Rhizoma),Yinchen(Artemisiae Scopariae Herba),Baishao(Paeoniae Radix Alba),Danggui(Angelicae Sinensis Radix),etc.;the results of association rules:Jigucao(Abriherba)-Kushen(Sophorae Flavescentis Radix),Jjiaogulan(Gynostemmatis Pentaphylli Rhizoma seu Herba)-Banlangen(lsatidis Radix),Huangqin(Scutellariae Radix)-Banlangen(lsatidis Radix),etc.;the results of cluster analysis showed that there were 10 clusters:(1)Yinchen(Artemisiae Scopariae Herba),Huanglian(Coptidis Rhizoma),Baihuasheshecao(Hedyotis Diffusae Herba),Banzhilian(Scutellariae Barbatae Herba),Jigucao(Abriherba);(2)Baishao(Paeoniae Radix Alba),Danggui(Angelicae Sinensis Radix),Chuanxiong(Chuanxiong Rhizoma),Wuyao(Linderae Radix);(3)Yuanhu(Corydalis Rhizoma),Danshen(Salviae Miltiorrhizae Radix et Rhizoma),Baizhi(Angelicae Dahuricae Radix).Conclusions For the treatment of AG concomitant with Hp infection,Professor Diangui Li mainly adopts the method of clearing heat and removing the toxin,regulating qi and resolving phlegm,combining disease differentiation with syndrome differentiation,performing reinforcing method,and reducing method simultaneously to regulate the mechanism of the human body.

Clinical usefulness of linked color imaging in identifying Helicobacter pylori infection:A systematic review and meta-analysis

BACKGROUND Accurate diagnosis of Helicobacter pylori(H.pylori)infection status is a crucial premise for eradication therapy,as well as evaluation of risk for gastric cancer.Recent progress on imaging enhancement endoscopy(IEE)made it possible to not only detect precancerous lesions and early gastrointestinal cancers but also to predict H.pylori infection in real time.As a novel IEE modality,linked color imaging(LCI)has exhibited its value on diagnosis of lesions of gastric mucosa through emphasizing minor differences of color tone.AIM To compare the efficacy of LCI for H.pylori active infection vs conventional white light imaging(WLI).METHODS PubMed,Embase,Embase and Cochrane Library were searched up to the end of April 11,2022.The random-effects model was adopted to calculate the diagnostic efficacy of LCI and WLI.The calculation of sensitivity,specificity,and likelihood ratios were performed;symmetric receiver operator characteristic(SROC)curves and the areas under the SROC curves were computed.Quality of the included studies was chosen to assess using the quality assessment of diagnostic accuracy studies-2 tool.RESULTS Seven original studies were included in this study.The pooled sensitivity,specificity,positive likelihood rate,and negative likelihood rate of LCI for the diagnosis of H.pylori infection of gastric mucosa were 0.85[95%confidence interval(CI):0.76-0.92],0.82(95%CI:0.78-0.85),4.71(95%CI:3.7-5.9),and 0.18(95%CI:0.10-0.31)respectively,with diagnostic odds ratio=26(95%CI:13-52),SROC=0.87(95%CI:0.84-0.90),which showed superiority of diagnostic efficacy compared to WLI.CONCLUSION Our results showed LCI can improve efficacy of diagnosis on H.pylori infection,which represents a useful endoscopic evaluation modality for clinical practice.

幽门螺杆菌感染对非酒精性脂肪性肝病患者肝脏炎症及纤维化无影响

目的:研究幽门螺杆菌(HP)感染与非酒精性脂肪性肝病(NAFLD)发生发展的相关性及HP感染与NAFLD患者肝脏炎症与纤维化程度的关系。方法:纳入3 133例体检人群进行回顾性横断面研究,分为NAFLD组及对照组,比较2组代谢相关指标及HP感染比例;将NAFLD组分为HP阳性组和HP阴性组,比较2组患者肝脏炎症和纤维化指标。结果:多因素Logistic回归分析显示,体质指数(BMI)增加(OR=1.366,95%CI:1.314~1.420,P<0.001)、糖代谢异常(OR=2.066,95%CI:1.628~2.621,P<0.001)、甘油三酯(TG)升高(OR=2.298,95%CI:1.928~2.739,P<0.001)、低密度脂蛋白(LDL)升高(OR=2.147,95%CI:1.535~3.005,P<0.001)、尿酸升高(OR=1.003,95%CI:1.002~1.005,P<0.001)是NAFLD的独立危险因素,HP感染不是NAFLD的独立危险因素(OR=1.146,95%CI:0.935~1.404,P=0.188)。NAFLD患者中,HP阳性与HP阴性患者比较,肝脏炎症相关指标及肝脏纤维化指标差异均无统计学意义(P均>0.05)。结论:BMI增加、糖代谢异常、TG升高、LDL升高、尿酸升高是NAFLD的独立危险因素,HP感染不是NAFLD的独立危险因素,HP感染对NAFLD患者肝脏炎症及肝纤维化无影响。

中西医结合治疗幽门螺杆菌相关性胃炎临床观察

目的:观察丹栀逍遥散合左金丸加减治疗幽门螺杆菌相关性胃炎的临床疗效。方法:将128例幽门螺杆菌相关性胃炎患者随机分为两组各64例,对照组予雷贝拉唑钠肠溶片、克拉霉素片、阿莫西林胶囊、枸橼酸铋钾胶囊治疗;治疗组在对照组基础上加用丹栀逍遥散合左金丸加减治疗。结果:治疗组幽门螺杆菌根除率为96.88%,明显高于对照组的81.25%,两组比较差异有统计学意义(P<0.05);治疗组总有效率96.88%,明显高于对照组的85.94%,两组比较差异有统计学意义(P<0.05);治疗组复发率1.56%,明显低于对照组的9.38%,两组比较差异有统计学意义(P<0.05)。结论:丹栀逍遥散合左金丸加减治疗幽门螺杆菌相关性胃炎临床疗效较好。

熊去氧胆酸联合常规西医治疗胆汁反流性胃炎合并幽门螺旋杆菌感染的疗效及对IL-8、PGE2的影响

目的探讨熊去氧胆酸联合常规西医治疗胆汁反流性胃炎(BRG)合并幽门螺旋杆菌(Hp)感染的疗效及对白细胞介素-8(IL-8)、PGE2(前列腺素E2)的影响。方法选取2019年5月—2021年5月巴彦淖尔市医院收治的100例Hp呼吸试验为阳性的BRG患者进行研究,应用随机数表法将其分为观察组与对照组,每组50例。对照组采取常规西医治疗(克拉霉素+奥美拉唑+阿莫西林),观察组在常规西医治疗基础上增加熊去氧胆酸素治疗,对比两组患者临床疗效,并应用酶联免疫吸附法检测治疗前后血清白细胞介素-8(IL-8)、PGE2(前列腺素E2)表达水平,对比胃泌素(GAS)、胃动素(MTL)、胆囊收缩素(CCK)表达水平以及不良反应情况。结果观察组治疗总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后两组患者血清IL-8水平降低,观察组低于对照组,PGE2水平升高,观察组高于对照组(P<0.05);治疗后两组患者血清CCK水平降低,观察组低于对照组,MTL、GAS水平升高,观察组高于对照组,差异有统计学意义(P<0.05);两组患者均无严重不良反应发生,且轻度不良反应比较,差异无统计学意义(P>0.05),但观察组Hp根除率高于对照组(P<0.05)。结论对胆汁反流性胃炎合并Hp感染患者在常规西医治疗的基础上增加熊去氧胆酸能够提升其临床疗效,降低患者炎症反应,提升胃动力,调节胃肠激素,提升Hp根除率,且安全性较高。

胃癌亚甲基四氢叶酸还原酶基因1298AC多态性与H.pylori感染的关系

目的 探讨重庆地区胃癌人群亚甲基四氢叶酸还原酶 (MTHFR)基因 12 98AC多态性及与H .pylori感染的关系。方法 采用聚合酶链反应和限制性片段长度多态性 (PCR RFLP)技术 ,检测 12 2例胃癌和 10 1例正常对照的MTHFR基因 12 98AC多态性 :采用PCR和Warthin Starry银染色法检测幽门螺杆菌 (H .pylori)。结果 胃癌组 12 98AA、12 98AC和12 98CC 3种基因型频率分别为 5 9.8%、3 6.1%和 4.1% ,与对照组中 3种基因型频率 5 7.4%、3 7.6%和 5 .0 %相比无显著差异 (P >0 0 5 )。以 12 98AA基因型的OR为 1.0 0 ,胃窦癌AC基因型的OR为 0 .87( 95 %CI,0 .42～ 1.82 ) ,CC基因型的OR为0 .41( 95 %CI ,0 .0 5～ 3 .72 )。胃癌MTHFR 12 98AC 3种基因型中H .pylori的检出率无明显差别 (P >0 0 5 )。结论 重庆地区人群中MTHFR 12 98AC多态性可能是胃窦癌的保护因素 ,MTHFR 12 98AC多态性与H .pylori感染无关。

SD大鼠H.pylori感染胃炎模型的建立

目的尝试在SPF级SD大鼠胃内定植H.pylori,以建立大鼠H.pylori感染胃炎模型。方法选用SD大鼠30只,随机分为5组,即对照组及4个模型组,模型组分别予NaHCO3溶液、56%酒精、消炎痛溶液、NaHCO3+消炎痛溶液联合H.pylori菌液灌胃造模,灌胃隔天1次,连续5次,并于最后一次灌胃结束后第2、4、6周处死大鼠,取胃黏膜组织分别记录损伤指数、进行快速尿素酶试验、胃黏膜涂片及病理切片。结果每组大鼠数、快速尿素酶试验及革兰染色阳性数:NaHCO3溶液+H.pylori组分别为6、4、4,56%酒精+H.pylori组分别为6、6、1,消炎痛溶液+H.pylori组分别为5、4、4,NaHCO3+消炎痛溶液+H.pylori组分别为4、4、4。损伤指数及病理切片:对照组胃黏膜形态正常,无损伤,各模型组胃黏膜肉眼观察均有不同程度的损伤,病理切片观察第2周有少量淋巴细胞浸润,第4周大量淋巴细胞及中性粒细胞浸润,腺体破坏,为活动性胃炎,第6周有大量淋巴细胞及中性粒细胞浸润,但损伤无进行性加重。结论 4种造模方式均可使H.pylori在SPF级大鼠胃内定植,定植时间至少长达6周,并能导致胃黏膜炎性损伤,损伤在第4周时最为严重,但以NaHCO3+消炎痛溶液+H.pylori造模最为成功,值得推广。

副干酪乳杆菌TK1501后生元的制备及对幽门螺旋杆菌的抑制作用

目的对副干酪乳杆菌(L.paracasei TK1501)发酵大豆产物中的后生元进行分离提取和体内外抑菌活性进行研究,评估该后生元在治疗幽门螺旋杆菌(Hp)感染的作用。方法L.paracasei TK1501在无氧密闭的环境内以37℃、固态发酵参数中料水比1∶1.5,接种量5×107 CFU/mL,培养发酵32 h后,通过大孔树脂XAD-16N吸附法、阳离子交换色谱法、高效液相色谱法分离纯化,对L.paracasei TK1501后生元进行稳定性及抗菌效果分析。将50只C57雄性小鼠随机分为空白组、模型组、阴性对照组、低剂量组(0.02 mL/只)和高剂量组(0.1 mL/只),10只/组,连续灌胃4周。取血清观察胃部炎症因子TNF-α、IL-1β表达水平变化,取小鼠胃组织进行HE染色。结果L.paracasei TK1501后生元易被蛋白酶降解,热稳定性好,对酸碱、有机溶剂等不利因素有较好的耐受性(P<0.05);在体外试验中,对金黄色葡萄球菌、Hp等均有较好的杀灭作用;在动物实验中,与模型组相比,L.paracasei TK1501后生元高剂量组明显改善Hp感染(P<0.05),胃部炎症因子TNF-α、IL-1β表达水平变化明显下降(P<0.05)。结论L.paracasei TK1501后生元对Hp、金黄色葡萄球菌等具有较好的抑制和杀灭效果,而在相同条件下对肠道中的正常菌群则无明显影响。

复方尿囊素与铋剂四联十日疗法治疗H.pylori阳性慢性胃炎患者的效果对比

目的观察复方尿囊素与铋剂四联疗法治疗H.pylori阳性慢性胃炎的治疗效果。方法将经胃镜诊断为H.pylori阳性慢性胃炎患者94例随机分为复方尿囊素组和铋剂组,每组47例。复方尿囊素组患者给予奥美拉唑20 mg/次,2次/d,四环素0.5 g/次,3次/d,呋喃唑酮0.1 g/次,3次/d,复方尿囊素3片/次,3次/d;铋剂组患者给予奥美拉唑20 mg/次,2次/d,四环素0.5 g/次,3次/d,呋喃唑酮0.1 g/次,3次/d,枸橼酸铋钾胶囊110 mg/次,4次/d。比较2组患者H.pylori根除率,临床症状改善效果,临床症状改善时间,不良反应和治疗后半年复发情况。结果复方尿囊素组患者H.pylori根除率、治疗有效率和显效率显著高于铋剂组(P<0.05)。复方尿囊素组患者上腹痛、腹胀、嗳气和反胃等临床症状改善时间显著低于铋剂组(P<0.01)。复方尿囊素组患者不良反应与铋剂组差异无统计学意义(P>0.05)。复方尿囊素组患者半年后复发率显著低于铋剂组(P<0.05)。结论复方尿囊素四联疗法治疗H.pylori阳性慢性胃炎的治疗效果更佳。

IL-1B基因多态性和H.pylori感染与汉族人胃癌的相关性研究

目的:通过比较胃癌患者与匹配人群的幽门螺旋杆菌(Helicobacter pylori,H.pylori)感染率和IL-1B基因多态性,探讨IL-1B基因多态性是否增加H.pylori感染后胃癌发生的危险性。方法:采用聚合酶链反应-限制性片段长度多态性(Restriction fragment length polymorphism,RFLP)分析法检测胃癌低发区84例胃癌患者和84例与之性别、年龄匹配的普通人群的lL-1B基因多态性。采用酶联免疫吸附法(Enzyme-linked immunosorbent assay,ELISA)检测上述人群中的H.pylori感染率。结果:①胃癌患者IL-1B-511T/T基因型频率显著高于性别、年龄匹配的对照人群(P<0·05),IL-1B-31T/T基因型频率在两组间无显著差异(P>0·05)。84例胃癌患者的H.pylori感染率显著高于对照人群(P<0·01)。胃癌患者H.pylori阳性感染者IL-1B-511T/T基因型个体显著多于对照人群。结论:H.pylori感染者胃癌组织中IL-1B-511T/T基因型为主,提示IL-1B-511T/T基因型可能增加H.pylori感染后中国汉族人群发生胃癌的危险性,而IL-1B-31基因型与H.pylori感染后中国汉族人群胃癌发生无显著相关性。

miRNA-218、miRNA-21在Hp感染相关胃癌组织中的表达及临床意义

目的探究微小RNA-218(miR-218)、miR-21在幽门螺旋杆菌(Helicobacter pylori,Hp)感染相关胃癌组织中的表达及临床意义。方法选取接受手术切除的胃癌患者104例,分析miR-218和miR-21表达与Hp感染胃癌患者临床病理因素及术后复发的关系。结果Hp阳性组患者胃癌组织中miR-218水平低于Hp阴性组,miR-21水平、2年复发率高于Hp阴性组(P均<0.05);Hp感染胃癌患者胃癌组织中miR-218水平低于癌旁组织,miR-21水平高于癌旁组织(P均<0.05);miR-218和miR-21表达与患者分化程度、TNM分期、肿瘤浸润深度、淋巴结转移及无疾病进展生存率相关,对术后2年复发情况具有较高的预测价值。结论miR-218和miR-21水平在Hp感染和无Hp感染的胃癌患者中存在差异表达,其异常表达与Hp感染胃癌患者临床病理因素及预后存在关联。

不同含米诺环素四联方案在幽门螺杆菌感染初治患者中的疗效及卫生经济学评价

目的评价不同含米诺环素四联方案在幽门螺杆菌(Hp)感染初治患者中的疗效及卫生经济学。方法回顾性分析2022年1月1日至2023年7月31日于首都医科大学附属北京积水潭医院接受含米诺环素四联方案根除治疗的554例Hp感染初治患者的临床资料。根据根除治疗方案的不同分为MAPB组(166例)、MMPB组(81例)和MLPB组(307例)。MAPB组为米诺环素-阿莫西林-质子泵抑制剂(PPI)-铋剂方案;MMPB组为米诺环素-甲硝唑-PPI-铋剂方案;MLPB组为米诺环素-左氧氟沙星-PPI-铋剂方案;3组疗程均为14 d。结局指标包括Hp根除率和不良反应发生率。以上述研究结果作为参数,分别采用多方案比较法和净效益法对所有治疗方案进行评估并筛选优势方案。通过敏感性分析评价所得结果的稳定性。结果MAPB组、MMPB组和MLPB组患者Hp根除率分别为92.8%(154/166)、84.0%(68/81)和94.1%(289/307),3组间比较差异有统计学意义(χ^(2)=9.382,P=0.009)。554例患者中185例(33.4%)在根除治疗期间报告了药物不良反应。其中,MMPB组患者不良反应发生率最高(46.9%),组间差异有统计学意义(χ^(2)=38.545,P<0.001)。多方案比较法结果显示,上述3种方案均非绝对劣势方案。多方案比较法和净效益法结果均显示,米诺环素-左氧氟沙星-PPI-铋剂方案为优势方案。敏感性分析结果显示,米诺环素-阿莫西林-PPI-铋剂方案的根除率对结果影响较大。结论含米诺环素四联方案用于Hp感染初治患者的根除治疗显示出较好的效果。其中,米诺环素-左氧氟沙星-PPI-铋剂方案可能具有最优的卫生经济学价值。

雷贝拉唑、雷尼替丁治疗H.pylori阴性胃溃疡的研究

目的探讨雷贝拉唑与雷尼替丁治疗H.pylori阴性胃溃疡的疗效和安全性。方法比较雷贝拉唑(20mg)与雷尼替丁(300 mg)治疗H.pylori阴性的胃溃疡患者的疗效。266例经内镜证实为胃溃疡,病理组织学排除H.pylori感染的患者被纳入本次研究。结果雷贝拉唑组177例患者4周后愈合率为96%,雷尼替丁组89例患者4周后愈合率为85%(P<0.01)。结论就溃疡愈合和症状缓解而言,雷贝拉唑疗效优于雷尼替丁。